A Phase 2 interventional study of Phentolamine Mesylate Ophthalmic Solution 1% and Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) in Decrease in Night Vision and Disturbance; Vision, Loss, sponsored by Opus Genetics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Opus Genetics, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study are:
To assess the effect of ophthalmic phentolamine mesylate in mesopic conditions on the four endpoints:
Double-masked, placebo-controlled, single-dose Phase 2 study in 24 patients experiencing severe night vision difficulties to evaluate ocular and systemic safety and efficacy following administration of one drop of phentolamine mesylate 1.0% QD in each eye for 1 day.
Opus Genetics, Inc is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 drop in each eye (QD) for one day.
Drug: Phentolamine Mesylate Ophthalmic Solution 1%
1 drop in each eye (QD) for one day.
Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Topical Sterile Ophthalmic Solution
Topical Sterile Ophthalmic Solution
Contrast Sensitivity
Average change in monocular contrast sensitivity scores under mesopic conditions at each of five spatial frequencies with and without glare. The tests were performed in a darkened room using the Optec 6500 instrument (Stereo Optical) using Slides 5-9 (spatial frequencies 1.5 - 18 cycles per degree), with the distance setting at "far", and with the light setting at "night". Subjects were asked to read each slide from left to right indicating if the lines were tilted to the left, the right or straight up and down until they provided 2 consecutive incorrect responses. The total number of correct responses for each slide was recorded.
Time frame: 1 day
Visual Acuity
Average number of letters of improvement in the following parameters: 1. Distance high-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters) 2. Distance high-contrast visual acuity under photopic conditions (monocular, measured at 4 meters) 3. Distance low-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters) 4. Distance low-contrast visual acuity under photopic conditions (monocular, measured at 4 meters)
Time frame: 1 day
Self-Reported Vision Quality
Subjective patient evaluations of vision quality at night (% rating their vision as improved)
Time frame: 1 day
Pupil Diameter
Average change in pupil diameter
Time frame: 1 day
24 subjects were enrolled. Both eyes were treated and evaluated for efficay and safety.
| Milestone | Phentolamine Mesylate Ophthalmic Solution 1% | Phentolamine Mesylate Ophthalmic Solution Vehicle |
|---|---|---|
| Started | 16 | 8 |
| Completed | 16 | 8 |
| Not completed | 0 | 0 |
Average change in monocular contrast sensitivity scores under mesopic conditions at each of five spatial frequencies with and without glare. The tests were performed in a darkened room using the Optec 6500 instrument (Stereo Optical) using Slides 5-9 (spatial frequencies 1.5 - 18 cycles per degree), with the distance setting at "far", and with the light setting at "night". Subjects were asked to read each slide from left to right indicating if the lines were tilted to the left, the right or straight up and down until they provided 2 consecutive incorrect responses. The total number of correct responses for each slide was recorded.
| Patches | Phentolamine Mesylate Ophthalmic Solution 1% | Phentolamine Mesylate Ophthalmic Solution Vehicle |
|---|---|---|
| 1.5 Cycles with Glare | 0.6 ± 1.8 | 0.8 ± 1.5 |
| 3 Cycles with Glare | 0.9 ± 2.1 | 0.7 ± 1.5 |
| 6 Cycles with Glare | 1.4 ± 1.9 | 0.1 ± 1.3 |
| 12 Cycles with Glare | 1.7 ± 2.0 | 0.4 ± 1.0 |
| 18 Cycles with Glare | 1.3 ± 1.8 | 0.3 ± 0.8 |
| 1.5 Cycles without Glare | 1.0 ± 1.4 | 0.4 ± 1.4 |
| 3 Cycles without Glare | 1.3 ± 1.5 | 0.7 ± 1.3 |
| 6 Cycles without Glare | 1.1 ± 1.4 | 0.5 ± 1.4 |
| 12 Cycles without Glare | 0.8 ± 1.6 | -0.2 ± 1.0 |
| 18 Cycles without Glare | 0.5 ± 1.4 | 0.3 ± 0.9 |
Average number of letters of improvement in the following parameters: 1. Distance high-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters) 2. Distance high-contrast visual acuity under photopic conditions (monocular, measured at 4 meters) 3. Distance low-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters) 4. Distance low-contrast visual acuity under photopic conditions (monocular, measured at 4 meters)
| Letters | Phentolamine Mesylate Ophthalmic Solution 1% | Phentolamine Mesylate Ophthalmic Solution Vehicle |
|---|---|---|
| Distance high-contrast visual acuity under mesopic conditions | 6.5 ± 7.2 | 1.1 ± 3.9 |
| Distance high-contrast visual acuity under photopic conditions | 3.8 ± 7.6 | 0.1 ± 3.8 |
| Distance low-contrast visual acuity under mesopic conditions | 8.0 ± 8.4 | 3.1 ± 4.5 |
| Distance low-contrast visual acuity under photopic conditions | 7.3 ± 6.6 | 0.9 ± 3.6 |
Subjective patient evaluations of vision quality at night (% rating their vision as improved)
| Percentage | Phentolamine Mesylate Ophthalmic Solution 1% | Phentolamine Mesylate Ophthalmic Solution Vehicle |
|---|---|---|
| Self-Reported Vision Quality | 69 | 75 |
Average change in pupil diameter
| mm | Phentolamine Mesylate Ophthalmic Solution 1% | Phentolamine Mesylate Ophthalmic Solution Vehicle |
|---|---|---|
| Pupil Diameter | -1.3 ± 0.8 | -0.2 ± 0.5 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phentolamine Mesylate Ophthalmic Solution 1% | — | 0/16 (0%) | 0/16 (0%) |
| Phentolamine Mesylate Ophthalmic Solution Vehicle | — | 0/8 (0%) | 0/8 (0%) |
24 subjects were enrolled. Both eyes were evaluated for efficacy and safety.
| Age, Continuous(years) | Phentolamine Mesylate Ophthalmic Solution 1% | Phentolamine Mesylate Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Mean | 42.1 ± 14.6 | 47.4 ± 13.5 | 43.9 ± 19.9 |
| Sex: Female, Male(Participants) | Phentolamine Mesylate Ophthalmic Solution 1% | Phentolamine Mesylate Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Female | 12 | 5 | 17 |
| Male | 4 | 3 | 7 |
| Pupil Diameter Illuminated(mm) | Phentolamine Mesylate Ophthalmic Solution 1% | Phentolamine Mesylate Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Mean | 4.4 ± 0.6 | 4.9 ± 0.8 | 4.6 ± 1 |
| Trans-Illuminated Low Contrast Visual Acuity(Letters) | Phentolamine Mesylate Ophthalmic Solution 1% | Phentolamine Mesylate Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Mean | 33.1 ± 5.4 | 30.1 ± 8.4 | 32.1 ± 10.0 |
Ran from Aug 2007 to primary completion in Oct 2007, 2 months.
Results were first posted in Feb 2024, 16 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phentolamine
Opus Genetics, Inc